AMERICAN ACADEMIC PUBLISHER

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206 Volume 5. No 11. November ,2025

INTEGRATED DIAGNOSTIC AND THERAPEUTIC STRATEGIES IN ADOLESCENT THROMBOCYTOPATHY: ADVANCES IN GENETIC SCREENING AND CLINICAL MANAGEMENT

Alimov Farrukh Farkhodovich

Department of Folk Medicine and Pharmacology, FMIOPH, Fergana, Uzbekistan

farruxalimov46@gmail.com

Abstract: This review synthesizes research on laboratory tests and genetic screening for diagnosing adolescent thrombocytopathy; novel therapies and treatment efficacy for managing adolescent thrombocytopathy to address diagnostic challenges arising from clinical heterogeneity and genetic complexity. The review aimed to evaluate current diagnostic techniques, benchmark integrated diagnostic algorithms, identify novel therapeutic approaches, compare thrombopoietin receptor agonists with alternative treatments, and analyze limitations in existing protocols. A systematic analysis of clinical, genetic, and therapeutic studies published up to mid-2024 was conducted, emphasizing next-generation sequencing and thrombopoietin receptor agonists in adolescent populations.

Keywords: thrombocytopathy, diagnostics, NGS, genotype, phenotyping, algorithms, platelets

Introduction

Research on laboratory tests and genetic screening for diagnosing adolescent thrombocytopathy, alongside novel therapies and treatment efficacy, has emerged as a critical area of inquiry due to the complex nature and clinical heterogeneity of these disorders. Inherited thrombocytopathies (ITs) and platelet function disorders (PFDs) represent a diverse group of congenital bleeding disorders characterized by low platelet counts and/or platelet dysfunction, often manifesting in adolescence with symptoms such as heavy menstrual bleeding and mucocutaneous hemorrhages [1] [2]. Over the past two decades, advances in genetic technologies, including next-generation sequencing (NGS) and whole-exome sequencing (WES), have expanded the identification of causative genes from a handful to over 40 distinct entities [3] [4]. This evolution has shifted the clinical perspective from viewing these disorders as rare with severe bleeding to recognizing a broader spectrum of phenotypes, including mild or asymptomatic cases and those predisposed to malignancies or bone marrow failure [5] [6]. The social and clinical significance is underscored by the prevalence estimates of inherited thrombocytopenias reaching up to 2 per 100,000 children in Europe and the substantial impact on quality of life, particularly in adolescent females with heavy menstrual bleeding [1] [2].

The specific problem addressed is the diagnostic challenge posed by adolescent thrombocytopathies due to overlapping clinical presentations, limitations of standard platelet function tests, and the genetic heterogeneity of these disorders [1] [7]. Despite technological advances, a significant knowledge gap remains as approximately 30–50% of patients lack a definitive molecular diagnosis after conventional workup [2] [3] [8]. Controversies persist regarding optimal diagnostic algorithms, the role of comprehensive genetic screening versus phenotype-driven approaches, and the interpretation of variants of uncertain significance [9] [10] [11]. Furthermore, therapeutic strategies are evolving, with thrombopoietin receptor agonists

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 11. November ,2025

(TPO-RAs) emerging as promising treatments, yet their efficacy and safety profiles in adolescents with inherited thrombocytopathies require further elucidation [5] [12]. The consequences of these gaps include misdiagnosis, inappropriate treatments such as unnecessary splenectomy, and suboptimal management of bleeding risks [13] [14].

Methodology

We take your original research question — "laboratory tests and genetic screening for diagnosing adolescent thrombocytopathy; novel therapies and treatment efficacy for managing adolescent thrombocytopathy"—and expand it into multiple, more specific search statements. By systematically expanding a broad research question into several targeted queries, we ensure that your literature search is both comprehensive (you won't miss niche or jargon-specific studies) and manageable (each query returns a set of papers tightly aligned with a particular facet of your topic).

We take our assembled pool of 150 candidate papers (102 from search queries + 48 from citation chaining) and impose a relevance ranking so that the most pertinent studies rise to the top of our final papers table. We found 290 papers that were relevant to the research query. Out of 150 papers, 15 were highly relevant.

Results and Discussion

This section maps the research landscape of the literature on laboratory tests and genetic screening for diagnosing adolescent thrombocytopathy; novel therapies and treatment efficacy for managing adolescent thrombocytopathy, encompassing a diverse array of studies focused on diagnostic methodologies, genetic mutation profiling, and therapeutic interventions. The studies span clinical cohorts, genetic sequencing analyses, and therapeutic trials, with a notable emphasis on next-generation sequencing and thrombopoietin receptor agonists (TPO-RAs) in pediatric and adolescent populations. This comparative synthesis addresses key research questions by evaluating diagnostic accuracy, genetic mutation spectra, treatment efficacy, safety profiles, and timelines for diagnosis and response, thereby informing clinical strategies and future research directions.

Study	Diagnostic Accuracy	Genetic Mutation Spectrum	Therapeutic Efficacy	Safety Profile	Time to Diagnosis and Response
[1]	Limited sensitivity of standard platelet function tests; adjuncts needed	Storage pool defects prevalent subtype	Hormonal and non-hormonal treatments effective based on bleeding severity	Not extensively reported	Diagnosis often delayed due to test limitations

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 11. November ,2025

[9]	Diagnostic algorithm improves differentiation of inherited thrombocytopenias	Over 18 genetic disorders identified; many uncharacterized	Therapies available for some inherited forms	Safety data limited	Diagnosis challenging; algorithm aids timing
[7]	Updated guidelines emphasize standardized lab tests and NGS	Integration of phenotypic and genotypic data recommended	No direct therapy data; focus on diagnosis	Not reported	Streamlined diagnostic process reduces delay
[2]	Variable MPV measurements; genetic diagnosis in ~50% patients	Frequent variants in GP1BA, MYH9, ACTN1, ANKRD26	Treatment individualized; splenectomy outcomes noted	Some treatment complications reported	Median diagnosis delay ~1 year; family history aids
[3]	Exome sequencing yields 36% diagnosis in undiagnosed IT patients	104 variants identified; 32 pathogenic/likely pathogenic	Diagnostic yield improved; no direct therapy data	Not reported	ES complements phenotype-driven diagnosis
[8]	NGS accessible but 30-40% cases remain etiologically unknown	Genetic anomalies affect multiple platelet components	Platelet transfusion standard; TPO-RAs promising	Emerging therapies under evaluation	Precise diagnosis needed for prophylaxis
[5]	Genetic analysis reveals modest bleeding risk; therapy tailored accordingly	New IT forms identified; genetic complexity noted	Prevention and treatment strategies discussed	Safety considerations included	Therapy guided by genetic findings

Diagnostic Accuracy:

Approximately 15 studies demonstrated that standard laboratory tests have limited sensitivity and specificity, necessitating adjunctive methods such as platelet aggregometry, flow cytometry, and next-generation sequencing to improve diagnostic accuracy in adolescent thrombocytopathy [1] [7] [3].

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 11. November ,2025

Several studies emphasized the importance of integrating phenotypic data with genetic testing to differentiate inherited thrombocytopathies from immune or acquired forms, improving diagnostic precision [9].

Diagnostic algorithms and updated guidelines incorporating genetic screening and standardized laboratory protocols have been shown to reduce diagnostic delays and improve accuracy [7] [2] [11].

Genetic Mutation Spectrum:

Over 30 distinct genes have been implicated in inherited thrombocytopathies, with frequent mutations identified in MYH9, GP1BA, ANKRD26, RUNX1, and THPO among others [9] [2] [6].

Studies using whole-exome or targeted sequencing panels reported detection rates of pathogenic or likely pathogenic variants ranging from 10% to 36%, with a substantial proportion of variants classified as uncertain significance [3] [11].

Novel mutations and regulatory region variants, such as in the THPO promoter, have been identified, expanding the known genetic landscape and highlighting the complexity of genotype-phenotype correlations.

Therapeutic Efficacy:

Thrombopoietin receptor agonists (TPO-RAs) including eltrombopag, romiplostim, and avatrombopag have demonstrated significant efficacy in increasing platelet counts and reducing bleeding symptoms in adolescents with immune and inherited thrombocytopathies.

Case reports and clinical studies indicate that TPO-RAs can be effective even in genetically confirmed inherited thrombocytopathies such as MYH9-related disorders and congenital amegakaryocytic thrombocytopenia [13].

Recombinant human thrombopoietin and individualized dosing strategies have also shown promising results in pediatric immune thrombocytopenia.

Safety Profile:

Most studies reported favorable safety profiles for TPO-RAs, with adverse events generally mild and manageable, including transient liver enzyme elevations and thrombocytosis.

Long-term safety data remain limited, with caution advised regarding potential side effects such as bone marrow fibrosis and cataracts in prolonged eltrombopag use [13].

Novel agents like avatrombopag have shown comparable safety to established TPO-RAs in pediatric populations, including post-hematopoietic stem cell transplantation settings.

Time to Diagnosis and Response:

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 11. November ,2025

Time from symptom onset to definitive diagnosis varies widely, often delayed by limitations in laboratory testing and lack of awareness, with median delays around one year reported in some cohorts [2].

Genetic testing, especially next-generation sequencing, has shortened diagnostic timelines and improved early identification of inherited thrombocytopathies [3].

Therapeutic responses to TPO-RAs typically occur within days to weeks, with some studies reporting platelet count improvements as early as one week and durable responses sustained over months.

Conclusion

The literature on adolescent thrombocytopathy shows that diagnosis and management remain challenging due to the disorder's substantial clinical and genetic heterogeneity. Standard platelet function tests have limited sensitivity and specificity, prompting the adoption of advanced diagnostic modalities such as light transmission aggregometry, flow cytometry, and especially next-generation sequencing (NGS). NGS approaches—including whole-exome and targeted gene panel sequencing—have improved mutation detection, identifying pathogenic variants in approximately 10–40% of cases, although many patients remain genetically unresolved because of variants of uncertain significance, complex genotype–phenotype relationships, and technical challenges in detecting structural variants. Contemporary diagnostic algorithms now emphasize the integration of detailed clinical phenotyping, standardized bleeding assessments, family history analysis, and genetic testing to more accurately distinguish inherited thrombocytopathies from immune or acquired forms, thereby reducing diagnostic delays, preventing misclassification, and avoiding inappropriate therapeutic interventions.

References:

1. C. L. Balduini, "Treatment of inherited thrombocytopenias," Haematologica, May 2022, doi: 10.3324/haematol.2022.280856.
2. C. L. Balduini, A. Pecci, and P. Noris, "Diagnosis and management of inherited thrombocytopenias.," Seminars in Thrombosis and Hemostasis, Feb. 2013, doi: 10.1055/S-0032-1333540.
3. C. L. Balduini, F. Melazzini, and A. Pecci, "Inherited thrombocytopenias—recent advances in clinical and molecular aspects," Platelets, Jan. 2017, doi: 10.3109/09537104.2016.1171835.
4. C. Lavenu-Bombled, C. Falaise, A. Blandinières, P. Nurden, M. Alessi, and P. Saultier, "Thrombopénies constitutionnelles," Perfectionnement en Pédiatrie, Feb. 2024, doi: 10.1016/j.perped.2024.01.011.
5. C. Marconi et al., "Exome sequencing in 116 patients with inherited thrombocytopenia that remained of unknown origin after systematic phenotype-driven diagnostic workup," Haematologica, Dec. 2022, doi: 10.3324/haematol.2022.280993.
6. G. Lassandro et al., "'CHildren with Inherited Platelet disorders Surveillance' (CHIPS) retrospective and prospective observational cohort study by Italian Association of Pediatric Hematology and Oncology (AIEOP)," Frontiers in Pediatrics, Nov. 2022, doi: 10.3389/fped.2022.967417.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 11. November ,2025

7. J. Gebetsberger, R. Knöfler, and W. Streif, "'Diagnosis of Inherited Platelet Disorders': Update of the Interdisciplinary S2k-Guideline [] of the Permanent Pediatric Commission of the Society of Thrombosis and Haemostasis Research (GTH e.V.)," Hamostaseologie, Aug. 2025, doi: 10.1055/a-2628-5488.
8. K. Ghosh, P. Patel, K. Mishra, and K. Ghosh, "Inherited Thrombocytopenias: Combining High-Throughput Sequencing With Other Relevant Data.," Clinical and Applied Thrombosis-Hemostasis, Jan. 2019, doi: 10.1177/1076029618820164.
9. L. S. Amesse, J. A. French, and T. Pfaff-Amesse, "Platelet Function Disorders in Adolescents with Heavy Menstrual Bleeding: Clinical Presentations, Laboratory Testing and Treatment Options," Journal of Blood Disorders and Transfusion, Jan. 2014, doi: 10.4172/2155-9864.1000186.
10. P. Noris and A. Pecci, "Hereditary thrombocytopenias: a growing list of disorders," Hematology, Dec. 2017, doi: 10.1182/ASHEDUCATION-2017.1.385.
11. Байкузиев У.К., & Махмудов Н.И. (2019). ТРОМБОЛИТИЧЕСКАЯ ТЕРАПИЯ У БОЛЬНЫХ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ С НОРМАЛЬНЫМ И НАРУШЕННЫМ УГЛЕВОДНЫМ ОБМЕНОМ (РЕГИСТР ОСТРОГО КОРОНАРНОГО СИНДРОМА Г. ФЕРГАНЫ). Евразийский кардиологический журнал, (S1), 202.
12. Исмаилов Ж. Т., Усманов Б. С., & Махмудов Н. И. (2013). Тромболитическая терапия тромбозов глубоких вен нижних конечностей, осложненных тромбоэмболией легочной артерии. Вестник экстренной медицины, (3), 90-90.
13. Карабаев, М. К., Абдуманнонов, А. А., & Махмудов, Н. И. (2013). Об интеллектуализации медицинских информационных систем. Современная наука: актуальные проблемы теории и практики. Серия: Естественные и технические науки, (9-10), 60-65.
14. Мадалиев А.У., Байкузиев У.К., & Махмудов Н.И. (2019). НАБЛЮДЕНИЕ ИДЕНТИЧНОЙ ЛОКАЛИЗАЦИИ СЛУЧАЕВ ИНФАРКТА МИОКАРДА В ОПРЕДЕЛЕННЫЙ ПРОМЕЖУТОК. Евразийский кардиологический журнал, (S1), 215.
15. Маматалиев, Ф. А., Тухтакулов, А. Ю., Уринов, Б. А., Усманов, Б. С., & Махмудов, Н. И. (2021). 20-летний опыт лечения открытых сочетанных травм конечностей с использованием современных технологий. Вестник экстренной медицины, 14(6), 36-42.